Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2020) 70 AEP172 | DOI: 10.1530/endoabs.70.AEP172

ECE2020 Audio ePoster Presentations Bone and Calcium (121 abstracts)

Primary hyperparathyroidism diagnosis with 18-F-fluorodioline Pet/CT (FCPCT) in a routine endocrinology praxis: Need of the new guidelines

Luc Schroeder 1 , Svetlana Smorodova 2 , Stefan Meilinger 1 , Sven Münks 1 , Maria Yaneva 3 , Michel Doat 4 , Florence Jonard 4 , Christian Picard 4 & Maria Tikhomirova 3


1Centre Hospitalier du Nord, ORL, Ettelbruck, Luxembourg; 2Privolzhsky Research Medical University, student, Nizhny Novgorod, Russian Federation; 3Centre Hospitalier du Nord, endocrinology, Ettelbruck, Luxembourg; 4Centre Hospitalier du Nord, nuclear medicine, Ettelbruck, Luxembourg


Background: Primary hyperparathyroidism (pHPT) is a common disease in a routine endocrinology praxis, but the biggest challenge is a localization of the adenoma and the further correct management of the disease. First FCPCT was reported in 2014 as the additional method of diagnosis of pHPT and in some centers has been already used as a first line diagnostic modality. However, FCPCT is still lacking in the European or International guidelines for the diagnosis of pHPT.

Methods: Patients with biochemical and clinical pHPT between January 2017 and august 2019 were included in the study. Baselines characteristic, clinical data, scan results and type of treatment were recorded.

Results: A total 39 patients (32 F) were included in the study, mean age at diagnosis 57.6 ± 11.7 (31–81), 21 patients were asymptomatic 54%. Osteoporosis was diagnosed at 45% of 11 patients by DEXA. One patient had previously diagnosed multiply fractures. 17 patients 45 % had positive Sestamibi scintigraphy and/or echography and/or Dual-isotope 99mTc-MIBI/123 Iwere successfully operated. 22 patients with inconclusive echography, Sestamibi scintigraphy and Dual-isotope 99mTc-MIBI/123 I received FCPT, 18 (81%) were positive and 16 later operated with positive outcome (100% specificity). Two patients refused the operation. Four negative: two patient did not receive any treatment, two remaining are clinically controlled under Mimpara.

Conclusion: In our little retrospective study we showed high detection rate per patient of FCH PT scan (81%) with operation after positive scan and Mimpara treatment by negative patient. We conclude that FCHPT should be included in the diagnosis and the treatment choice of pHPT. Moreover, the current guidelines should be added FCPT as diagnostic possibility by inconclusive other modalities.

Volume 70

22nd European Congress of Endocrinology

Online
05 Sep 2020 - 09 Sep 2020

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.